Order Now, Ships Today
One-time
These products are for laboratory research only and not intended for medical use. They are not FDA-approved to diagnose, treat, cure, or prevent any disease. By purchasing, you certify they will be used solely for research and not for human or animal consumption.
Tesofensine is a research-grade small-molecule triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine). Each capsule contains 500 mcg of tesofensine, supplied in a 100-capsule bottle for controlled oral-dosing research models.
This research compound is verified at ≥99% purity by HPLC and/or LC-MS. Each lot-specific Certificate of Analysis confirms identity (tesofensine, C₁₇H₂₃Cl₂NO), purity, potency (500 mcg/capsule) and absence of common residual solvents and heavy metals within internal limits.
Products from Elite Miami Peptides do not include usage instructions, as they are strictly for in vitro research and prohibited by law for human or animal use. Misuse or unlawful application will result in permanent denial of service.
Each vial contains exactly what’s indicated on the label. For instance, a 10mg vial contains precisely 10mg of lyophilized peptide. Researchers may divide it into smaller research portions—such as four 2.5mg aliquots—but the total content remains the same.
Yes. All peptides are supplied in lyophilized powder form and do not come reconstituted. Any extra materials required for research, such as solvents or diluents, must be obtained separately.
When stored as a dry powder, peptides remain stable for up to 2 years.
Once reconstituted, the solution should be kept refrigerated and is typically stable for up to 2 months under proper storage conditions.
Tesofensine is a phenyltropane-derived monoamine transporter inhibitor that blocks the reuptake of norepinephrine, serotonin and dopamine. In preclinical and clinical research, this mechanism has been used to study central appetite signalling, energy balance and body-weight regulation.
In simple terms, tesofensine is a lab-only molecule that affects brain chemicals linked to hunger and reward. Researchers use it in models to better understand how changing these signalling pathways can influence food intake, metabolism and weight-related biology. It is not approved for human treatment and is supplied strictly for research use only.
⚠️ Disclaimer: this product is not approved for medical use and is not intended to diagnose, treat, or prevent any disease. All information provided is for educational and research purposes only, and this product must never be used in humans or animals.
Tesofensine was originally investigated as a potential therapy for neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease. Early trials showed limited benefit for those indications but consistently reported reduced body weight as an off-target effect, shifting interest toward its use in obesity-focused research and appetite regulation models.
Tesofensine is a phenyltropane derivative with the IUPAC name (1R,2R,3S)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane. It has the molecular formula C₁₇H₂₃Cl₂NO and a molecular weight of approximately 328.3 g/mol.
Across diet-induced obesity models, tesofensine has been shown to reduce food intake, increase subjective satiety, and produce sustained body-weight reductions versus control groups. Studies report enhanced nighttime energy expenditure and improved glycemic control compared with several reference agents, effects attributed to combined norepinephrine, serotonin and dopamine reuptake inhibition in hypothalamic and mesolimbic circuits.
Research so far suggests that tesofensine helps scientists explore how changing key brain transmitters can impact appetite, calorie burning and blood-sugar handling in experimental systems. The data available are preclinical or early-stage clinical and are intended to inform mechanistic and pharmacology research only, not to support medical use.
Axel A.M.D. et al. (2010). Triple monoamine reuptake inhibition and appetite suppression in diet-induced obese rats. Neuropsychopharmacology. Nature Hansen H.H. et al. (2010). Tesofensine-induced weight loss and glycemic control in obese rat models. European Journal of Pharmacology. PLOS +1 Appel L. et al. (2014). Clinical evaluation of tesofensine, a triple monoamine reuptake inhibitor, in obesity research. Obesity (Silver Spring). PubMed Gilbert J. & Gasteyger C. (2012). Effects of tesofensine on appetite sensations and body weight. Semantic Scholar
Our specialists respond within minutes to any order or product inquiry.
These products are for laboratory research only and not intended for medical use. They are not FDA-approved to diagnose, treat, cure, or prevent any disease. By purchasing, you certify they will be used solely for research and not for human or animal consumption.
By clicking the button above, you agree to receive marketing text messages from Elite Miami Peptides at the number provided. Consent is not a condition of purchase. Msg & data rates may apply. Reply STOP to cancel, HELP for help. View our Privacy Policy.
All compounds from Elite Miami Peptides are intended strictly for laboratory research purposes.
They are not for human use, consumption, or therapeutic applications.
Products are supplied exclusively to qualified professionals working in compliance with all applicable laws and regulations.
